Rafferty Asset Management Portfolio holdings
AUM
$30.3B
1-Year Return
18.89%
This Quarter Return
+13.66%
1 Year Return
+18.89%
3 Year Return
+101.02%
5 Year Return
+164.75%
10 Year Return
+314.44%
AUM
$14.8B
AUM Growth
+$2.81B
(+24%)
Cap. Flow
+$1.69B
Cap. Flow
% of AUM
11.44%
Top 10 Holdings %
Top 10 Hldgs %
32.19%
Holding
1,185
New
65
Increased
729
Reduced
346
Closed
45
Top Buys
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$329M |
| 2 |
iShares China Large-Cap ETF
FXI
|
+$105M |
| 3 |
Texas Instruments
TXN
|
+$90.9M |
| 4 |
Tesla
TSLA
|
+$80.1M |
| 5 |
Intel
INTC
|
+$76M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$46.7M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$46.1M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$26.7M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$18.7M |
| 5 |
JPMorgan Chase
JPM
|
+$18.4M |
Sector Composition
| 1 | Technology | 42.09% |
| 2 | Financials | 11.46% |
| 3 | Healthcare | 8.37% |
| 4 | Energy | 5.47% |
| 5 | Consumer Discretionary | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
276
Deere & Co
DE
$128B
| $7.29M | 0.05% |
17,654
+802
| +5% | +$331K |
|
277
Ionis Pharmaceuticals
IONS
$10.2B
| $7.29M | 0.05% |
203,887
-15,092
| -7% | -$539K |
|
|
BPMC
278
DELISTED
Blueprint Medicines
BPMC
| $7.28M | 0.05% |
161,890
-8,792
| -5% | -$396K |
|
279
TG Therapeutics
TGTX
$5.07B
| $7.26M | 0.05% |
483,035
-268,744
| -36% | -$4.04M |
|
280
Novavax
NVAX
$1.34B
| $7.23M | 0.05% |
1,043,277
+554,753
| +114% | +$3.84M |
|
281
Kraft Heinz
KHC
$31.1B
| $7.22M | 0.05% |
186,623
+30,627
| +20% | +$1.18M |
|
282
Apellis Pharmaceuticals
APLS
$3.2B
| $7.22M | 0.05% |
109,398
-54,706
| -33% | -$3.61M |
|
283
Constellation Energy
CEG
$99.6B
| $7.21M | 0.05% |
91,869
+20,137
| +28% | +$1.58M |
|
284
Zoetis
ZTS
$65.9B
| $7.21M | 0.05% |
43,325
+1,285
| +3% | +$214K |
|
285
Alkermes
ALKS
$4.53B
| $7.21M | 0.05% |
255,668
-72,350
| -22% | -$2.04M |
|
286
CoStar Group
CSGP
$36.9B
| $7.19M | 0.05% |
104,386
+18,166
| +21% | +$1.25M |
|
287
Neurocrine Biosciences
NBIX
$14.3B
| $7.19M | 0.05% |
70,988
+2,334
| +3% | +$236K |
|
288
CRISPR Therapeutics
CRSP
$5.07B
| $7.12M | 0.05% |
157,446
-7,206
| -4% | -$326K |
|
289
Revolution Medicines
RVMD
$8.66B
| $7.1M | 0.05% |
327,586
+90,268
| +38% | +$1.96M |
|
290
First Horizon
FHN
$11.4B
| $7.09M | 0.05% |
398,686
+314,011
| +371% | +$5.58M |
|
291
Keurig Dr Pepper
KDP
$37B
| $7.09M | 0.05% |
200,857
+29,989
| +18% | +$1.06M |
|
292
Ultragenyx Pharmaceutical
RARE
$3.02B
| $7.04M | 0.05% |
175,575
-22,725
| -11% | -$911K |
|
293
Equinix
EQIX
$78.1B
| $7.01M | 0.05% |
9,721
+1,232
| +15% | +$888K |
|
294
Vir Biotechnology
VIR
$711M
| $7M | 0.05% |
300,846
-7,581
| -2% | -$176K |
|
295
Natera
NTRA
$23.3B
| $6.98M | 0.05% |
125,748
-85,702
| -41% | -$4.76M |
|
|
SAGE
296
DELISTED
Sage Therapeutics
SAGE
| $6.95M | 0.05% |
165,731
+1,874
| +1% | +$78.6K |
|
|
KRTX
297
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $6.89M | 0.05% |
37,955
-3,097
| -8% | -$563K |
|
298
Prothena Corp
PRTA
$454M
| $6.87M | 0.05% |
141,689
+3,336
| +2% | +$162K |
|
299
BioCryst Pharmaceuticals
BCRX
$1.69B
| $6.84M | 0.05% |
820,521
+52,448
| +7% | +$437K |
|
300
Cigna
CI
$82.1B
| $6.83M | 0.05% |
26,739
+479
| +2% | +$122K |
|